Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice
Authors:
- Hidefumi ItoHIHidefumi Ito
- Reika WateRWReika Wate
- Jianhua ZhangJZJianhua Zhang
- Shizuo OhnishiSOShizuo Ohnishi
- Satoshi KanekoSKSatoshi Kaneko
- Hisashi ItoHIHisashi Ito
- Satoshi NakanoSNSatoshi Nakano
- Hirofumi KusakaHKHirofumi Kusaka
- 1 October 2008
- journal article
- research article
- Published by Elsevier in Experimental Neurology
- Vol. 213 (2) , 448-455
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Guidelines for the Early Management of Adults With Ischemic StrokeStroke, 2007
- The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJournal of Neurochemistry, 2007
- Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondriaJournal of Zhejiang University-SCIENCE B, 2006
- The free-radical scavenger, edaravone, augments NO release from vascular cells and platelets after laser-induced, acute endothelial injuryin vivoPlatelets, 2006
- Therapeutic developments in the treatment of amyotrophic lateral sclerosisExpert Opinion on Investigational Drugs, 2002
- A Pharmacokinetic Study of MCI-186, a Novel Drug for Cerebrovascular Disease in Elderly and Young Health Subjects.Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 1997
- Impaired copper binding by the H46R mutant of human Cu,Zn superoxide dismutase, involved in amyotrophic lateral sclerosisFEBS Letters, 1994
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993
- Effect of MCI-186 on brain edema in rats.Stroke, 1989
- Permanent changes in muscle and motoneurones induced by nerve injury during a critical period of development of the ratDevelopmental Brain Research, 1987